Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 9015-68-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of asparaginase during breastfeeding. Because aspariginase is a large protein molecule with a molecular weight of about 140,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] However, the manufacturer recommends that breastfeeding be discontinued during asparaginase therapy and for 1 week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
- 2.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Asparaginase
CAS Registry Number
9015-68-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Enzymes
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Pegaspargase.[Drugs and Lactation Database (...]Review Pegaspargase.. Drugs and Lactation Database (LactMed®). 2006
- Review Crisantaspase Recombinant (Rylaze): CADTH Reimbursement Recommendation: Indication: As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase[ 2023]Review Crisantaspase Recombinant (Rylaze): CADTH Reimbursement Recommendation: Indication: As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase. 2023 May
- Review Luspatercept.[Drugs and Lactation Database (...]Review Luspatercept.. Drugs and Lactation Database (LactMed®). 2006
- Review Mosunetuzumab.[Drugs and Lactation Database (...]Review Mosunetuzumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Tafasitamab.[Drugs and Lactation Database (...]Review Tafasitamab.. Drugs and Lactation Database (LactMed®). 2006
- Asparaginase - Drugs and Lactation Database (LactMed®)Asparaginase - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...